Pharmadrug Inc
OTC Pink - Current Information:LMLLFView on Canadian Exchange

  • LAST PRICE
    0.0142
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 0.0142
  • Day Range
    ---
  • 52 Week Range
    0.0042
    0.0575
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 15, 2024

      Show headlines and story abstract

    • 5:31PM ET on Friday Nov 15, 2024 by Newsfile
      Companies Mentioned: LMLLF

      Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines and naturally-derived approved drugs, is pleased to announce that further to its press release dated October 31, 2024, it has completed the issuance of $412,552.94 principal amount of debentures to replace currently outstanding secured convertible debentures and a total of 8,251,058 common share purchase warrants (each a "Warrant").

    • 5:31PM ET on Friday Nov 15, 2024 by Dow Jones
      Companies Mentioned: PHRX

      Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines and naturally-derived approved drugs, is pleased to announce that further to its press release dated October 31, 2024, it has completed the issuance of $412,552.94 principal amount of debentures to replace currently outstanding secured convertible debentures and a total of 8,251,058 common share purchase warrants (each a "Warrant").

  • Oct 31, 2024

      Show headlines and story abstract

    • 5:56PM ET on Thursday Oct 31, 2024 by Newsfile
      Companies Mentioned: LMLLF

      Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it will be issuing $414,523 to replace currently outstanding secured convertible debentures and a total of 8,290,000 common share purchase warrants (each a "Warrant").

    • 5:56PM ET on Thursday Oct 31, 2024 by Dow Jones
      Companies Mentioned: PHRX

      Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it will be issuing $414,523 to replace currently outstanding secured convertible debentures and a total of 8,290,000 common share purchase warrants (each a "Warrant").

    • 8:59AM ET on Thursday Oct 31, 2024 by Dow Jones
      Companies Mentioned: PHRX

      Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing it has successfully completed its stability study of its patented enteric-coated cepharanthine formulation ("PD-001"), which supports the manufacturing of clinical trial material of PD-001 for use in the Company's first-in-human Phase 1 clinical study (the "Study") as a potential treatment for viral infectious diseases. As announced on August 19, 2024, Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), received approval by the Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study (the "Study") to support PD-001 as a potential treatment for viral infectious diseases.

Peers Headlines

No documents available